TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia

Bueno, Clara; Martínez, Alba; Romecín, Paola; Zanetti, Samanta Romina; Tirtakusuma, Ricky; Genescà, Eulàlia; Camós, Mireia; Ramírez-Orellana, Manuel; Anguita, Eduardo; Ballerini, Paola; Locatelli, Franco; Fuster, José Luís; Menéndez, Pablo

doi:10.3324/haematol.2022.282394

Cited by 1 publication

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Different Targets Of Car‐t For Amlmentioning

confidence: 99%

“…T‐cell immunoglobulin mucin‐3 (Tim‐3) is a transmembrane protein belonging to the TIM family that is expressed on almost all forms of AML primitive cells but not on HSCs, making it a promising target. 82 The main cause of leukaemia relapse after chemotherapy is resistance to LSCs because they cannot target the elimination of LSCs. In one study, researchers created a phage library from which anti‐human TIM antibodies were isolated and evaluated the killing ability of second‐generation TIM3 CAR‐T cells against leukaemia cell lines and primary AML cells in vitro and found that they had good anti‐leukaemia activity.…”

Section: Different Targets Of Car‐t For Amlmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in CAR‐T cell therapy for acute myeloid leukaemia

Gao,

Li,

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Acute myeloid leukaemia (AML) is a fatal and refractory haematologic cancer that primarily affects adults. It interferes with bone marrow cell proliferation. Patients have a 5 years survival rate of less than 30% despite the availability of several treatments, including chemotherapy, allogeneic haematopoietic stem cell transplantation (Allo‐HSCT), and receptor antagonist drugs. Allo‐HSCT is the mainstay of acute myeloid leukaemia treatment. Although it does work, there are severe side effects, such as graft‐versus‐host disease (GVHD). In recent years, chimeric antigen receptor (CAR)‐T cell therapies have made significant progress in the treatment of cancer. These engineered T cells can locate and recognize tumour cells in vivo and release a large number of effectors through immune action to effectively kill tumour cells. CAR‐T cells are among the most effective cancer treatments because of this property. CAR‐T cells have demonstrated positive therapeutic results in the treatment of acute myeloid leukaemia, according to numerous clinical investigations. This review highlights recent progress in new targets for AML immunotherapy, and the limitations, and difficulties of CAR‐T therapy for AML.

show abstract

Section: Different Targets Of Car‐t For Amlmentioning

confidence: 99%

Section: Different Targets Of Car‐t For Amlmentioning

confidence: 99%